Roche recently announced the launch of a new blood test kit called Elecsys AMH (anti-mullerian hormone). The new fertility test kit evaluate female’s ovarian reserve function according to indication of AMH levels in her blood.
AMH is an important fertility marker that health care professionals use it to assess women's ovarian reserve levels. AMH blood testing can be performed on any day of the menstrual cycle, and AMH is an excellent indicator of ovarian reserve compared with follicle stimulating hormone (FSH) and estradiol. The Elecsys AMH kit is the first fully automated anti-Mullerian hormone (AMH) test kit. In addition, the Elecsys AMH Blood Test Kit produces standardized results,while the result are often dependent on the operator or clinic when ultrasound is used to assess ovarian reserve.
The introduction of the Elecsys AMH kit will enable health care professionals to incorporate AMH testing into routine clinical practice. It can be more faster to get reliable test results compared to the traditional program and artificial AMH detection.
In the future, the Elecsys AMH kit will be used in conjunction with the new human recombinant follicle stimulating hormone (RFSH) drug, which is currently in Phase III clinical practice.
The Elecsys AHM Blood Test Kit will be available on all CE Marking markets in Europe, Latin America, the Middle East, Africa and Asia. But will not be available in the US or Japan.
According to the survey of World Health Organization (WHO), fertility problems plague about 10% of couples, affecting up to 80 million people worldwide, and this number is rising. The introduction of the Elecsys AMH kit is an important example of Roche's focus on improving women's health.